China To Issue Plan For Invigorating Bioindustry
This article was originally published in PharmAsia News
Executive Summary
China's National Development and Reform Commission is pushing for the development of the bioindustry, which so far has been little impacted by the global financial crunch. The sector grew 25.5 percent in 2008, hitting over RMB 860 billion in production value. NDRC has submitted policies for invigorating the industry to the State Council for approval. Three key national science and technology projects will commence this year - AIDS, prevention and treatment of viral hepatitis, as well as transgenic research. In addition, NDRC will work closely with the nine key bioindustry projects under China's Eleventh Five-Year Plan (2006-2011) to focus on the commercialization of green agricultural products, microorganism production, as well as modern TCM. (Click here for more - Chinese Language)
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.